Dr. Winer on the Tolerability of ALKS 4230 Plus Pembrolizumab in Ovarian Cancer

In Partnership With:

Society for Immunotherapy of Cancer

Ira Winer, MD, PhD, discusses the tolerability of ALKS 4230 plus pembrolizumab in ovarian cancer.

Ira Winer, MD, PhD, associate professor, Division of Gynecologic Oncology, Wayne State University, Barbara Ann Karmanos Cancer Institute, discusses the tolerability of ALKS 4230 plus pembrolizumab (Keytruda) in ovarian cancer.

Findings from the ongoing phase 1/2 ARTISTRY-1 trial were presented during the 2020 SITC Virtual Congress.

The results demonstrated objective responses with the combination of ALKS 4230, an investigational engineered cytokine, and pembrolizumab in patients with heavily pretreated, platinum-resistant ovarian cancer.

The ARTISTRY-1 regimen is intensive, but patients appeared to tolerate the combination well, says Winer.

Moreover, the responses appear durable, Winer concludes.

Related Videos
Jubilee Brown, MD, professor, director, gynecologic oncology, Levine Cancer Institute, Atrium Health
Lisa A. Carey MD, ScM, FASCO
Patrick I. Borgen, MD
Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C)
Steven J. Chmura, MD, PhD
Kevin Kalinsky, MD, MS
Kelly K. Hunt, MD, FACS, FSSO
Laura J. Esserman, MD, MBA
Phillip J. Koo, MD, division chief of Diagnostic Imaging, Northwest Region Oncology physician executive, the Banner MD Anderson Cancer Center in Phoenix, Arizona,
Paul L. Nguyen, MD, senior physician, director, Genitourinary Clinical Center for Radiation Oncology, Dana-Farber Cancer Institute, professor of radiation oncology, Harvard Medical School,
Related Content